1,358 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Gilead's (GILD) Earnings Miss Estimates in Q3, Sales Beat http://www.zacks.com/stock/news/584147/gileads-gild-earnings-miss-estimates-in-q3-sales-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-584147 Oct 25, 2019 - Gilead (GILD) falls short of earnings estimates but marginally beats on sales in the third quarter of 2019.
Core Laboratories NV (CLB) Q3 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/10/24/core-laboratories-nv-clb-q3-2019-earnings-call-tra.aspx?source=iedfolrf0000001 Oct 24, 2019 - CLB earnings call for the period ending September 30, 2019.
Arcadis NV 2019 Q3 - Results - Earnings Call Presentation https://seekingalpha.com/article/4298697-arcadis-nv-2019-q3-results-earnings-call-presentation?source=feed_all_articles Oct 24, 2019 - The following slide deck was published by Arcadis NV in conjunction with their 2019 Q3 earnings call.
Core Laboratories NV (CLB) CEO David Demshur on Q3 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4298683-core-laboratories-nv-clb-ceo-david-demshur-q3-2019-results-earnings-call-transcript?source=feed_sector_transcripts Oct 24, 2019 - Core Laboratories NV (NYSE:CLB) Q3 2019 Earnings Conference Call October 24, 2019, 08:30 ET Company Participants David Demshur - CEO & Chairman Gwendolyn Schreffler - SVP, Corporate Development &a
MELEXIS NV IEPER (MLXSF) CEO Françoise Chombar on Q3 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4298368-melexis-nv-ieper-mlxsf-ceo-francoise-chombar-q3-2019-results-earnings-call-transcript?source=feed_sector_transcripts Oct 23, 2019 - MELEXIS NV IEPER (OTC:MLXSF) Q3 2019 Earnings Conference Call October 23, 2019 11:00 ET Company Participants Françoise Chombar - CEO Karen Van Griensven - CFO Conference Call Participants Matthias Mae
Is a Beat in Store for Glaxo (GSK) This Earnings Season? http://www.zacks.com/stock/news/579086/is-a-beat-in-store-for-glaxo-gsk-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-579086 Oct 23, 2019 - Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales growth in the third quarter.
MELEXIS NV IEPER 2019 Q3 - Results - Earnings Call Presentation https://seekingalpha.com/article/4298113-melexis-nv-ieper-2019-q3-results-earnings-call-presentation?source=feed_all_articles Oct 23, 2019 - The following slide deck was published by MELEXIS NV IEPER in conjunction with their 2019 Q3 earnings call.
Novartis AG (NVS) CEO Vasant Narasimhan - CEO on Q3 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4298005-novartis-ag-nvs-ceo-vasant-narasimhan-ceo-q3-2019-results-earnings-call-transcript?source=feed_sector_healthcare Oct 22, 2019 - Novartis AG (NYSE:NVS) Q3 2019 Results Earnings Conference Call October 22, 2019, 08:00 AM ET Company Participants Samir Shah - Global Head of IR Vasant Narasimhan - CEO Harry Kirsch - CFO John Tsai -
Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More http://www.zacks.com/stock/news/577360/drug-biotech-stock-q3-earnings-on-oct-23-lly-alxn-more?cid=CS-ZC-FT-analyst_blog:_earnings_preview_-_esp|earnings_preview_-_esp-577360 Oct 22, 2019 - Four drug/biotech stocks are scheduled to release third-quarter results on Oct 23. Let's see how these companies are placed before their earnings call.
Novartis (NVS) Q3 Earnings & Sales Beat Estimates, Up Y/Y http://www.zacks.com/stock/news/577246/novartis-nvs-q3-earnings-sales-beat-estimates-up-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-577246 Oct 22, 2019 - Novartis (NVS) beats sales estimates in the third quarter of 2019, driven by robust performance of key drugs and increased contribution from new launches.

Pages: 123456789...136

<<<Page 4>